Compare Eli Lilly And Co (LLY) vs MasTec Inc (MTZ) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

MasTec (MTZ) trades at $336.61, up 2.13% with strong analyst support (88.9% buy ratings) and a consensus price target of $497.45. The stock shows a bearish technical signal despite recent earnings beats, with Q1 2026 EPS of $1.39 surpassing expectations. The company's $1.65 billion acquisition of Superior Group positions it to capitalize on AI-driven data center infrastructure demand, supported by a record $20.3 billion backlog. Valuation metrics include a P/E of 57.72 and ROE of 14.53%, indicating premium pricing but solid profitability.

Outlook remains positive due to infrastructure spending tailwinds and strategic acquisitions, though high valuation and integration risks from the Superior deal warrant caution. Revenue growth is projected to rise from $14.30 billion in 2025 to $15.30 billion in 2026, with net income margin improving to 2.94%. Key risks include execution challenges and macroeconomic sensitivity, but institutional bullishness suggests upside potential if earnings momentum continues.